BeiGene Officially Breaks Ground on New Jersey Manufacturing and Clinical R&D Center
Facility will feature biologic manufacturing, along with late-stage research and clinical development of cancer medicines
BeiGene, Ltd., a global biotech company that develops and commercializes cancer medicines, announced the groundbreaking of its flagship US manufacturing and clinical R&D center at the Princeton West Innovation Campus in Hopewell, NJ. Pharmaceutical Commerce originally reported on the firm’s purchase agreement to acquire the approximately 42-acre site with over one million square feet of developable real estate back in August 2021.
This will mark BeiGene’s sixth location in the US.
The initial phase of construction is expected to include approximately 400,000 square feet of dedicated commercial-stage biologic pharma manufacturing space, with capacity for up to 16,000 liters of biologics formula.
“Our planned flagship US R&D and manufacturing center supports our commitment to fight for life for people living with cancer around the world, through state-of-the-art commercial-stage biologic pharmaceutical manufacturing, late-stage research and clinical development capabilities,” says John Oyler, co-founder, chairman and CEO of BeiGene. “The Princeton-Hopewell area is an excellent location for BeiGene and the thriving life science community, with a deep talent pool as we continue to advance our pipeline of innovative cancer medicines and work to diversify our global supply chain.”
Understanding the FDA's Exemption for DSCSA Compliance
November 12th 2024In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.
